Loading...
•
Sep 30, 2021
Zevra Q3 2021 Earnings Report
Reported third quarter financial results and corporate updates.
Key Takeaways
KemPharm reported Q3 2021 revenue of $2.0 million and a net loss of $0.05 per basic share. Total cash and cash equivalents were $131.5 million as of September 30, 2021. The U.S. commercial launch of AZSTARYS® was initiated on July 21, 2021.
Richard W. Pascoe appointed as Executive Chairman.
Company uplisted to The Nasdaq Global Select Market.
U.S. commercial launch of AZSTARYS initiated on July 21, 2021.
AZSTARYS data presented at multiple medical conferences during ADHD Awareness Month.
Zevra
Zevra
Forward Guidance
KemPharm is focused on expanding its pipeline and commercialization capabilities, with the advancement of the SDX program and data from the ongoing SDX clinical trial expected before year-end.
Positive Outlook
- Continued commercialization of AZSTARYS.
- Further development of KemPharm’s pipeline of product candidates.
- Advancement of SDX program.
- Data from ongoing SDX clinical trial expected before year-end.
- Focus on pipeline development opportunities.
Challenges Ahead
- Uncertainties and risks that could significantly affect current plans.
- Risks described in detail in KemPharm’s Quarterly Report on Form 10-Q.
- No obligation to update or alter forward-looking statements.
- Potential impact of market conditions on commercialization efforts.
- Dependence on Corium's commercialization of AZSTARYS.